Re: Re: LDN Website Update - May 31, 2008

[Guest guest]

I lost the original; post on this. Was the trial for 8 weeks on LDN, or 4 weeks LDN and then another 4 on Placebo? I was confused as to how it was stated. OR did I understand that they switched the LDN and placebo groups - in other words - two groups of test subjects.n T <callisto_11uk@...> wrote: Thanks for the updates ! - I have a comment/question regarding the trial conducted by Dr Bruce Cree (below):Are there any more details about the time of

day LDN was administered/taken by the trial subjects? I seem to recall a previous study (Italian? German?) showed similar results but it transpired that the subjects took LDN in the morning, not at night, ...which, it would seem, would affect the efficacy of the drug. I wondered if this was perhaps the reason why Dr Cree's trial showed such dissappointing results as far as physical improvements were concerned. It's a thought isnt it? Or perhaps eight weeks was too short a time to show measureable physical improvements maybe? Perhaps we'll just have to wait for the full details of the trial to be published to answer these questions though. All the best to everyone on the board, n xx(UK) >> LDN Website Update - May 31, 2008> www.low dose naltrexone.org / www.ldninfo.org> > Latest News as of May 2008:> > Outline of Double-Blind Trial of LDN in MS Presented at AAN> > Dr. Bruce Cree and colleagues of the University of California at San Francisco delivered a > poster presentation summary of their recently completed trial to the American Academy of > Neurology (AAN) conference in April 2008 in Chicago. Eighty patients with MS were > involved in this double-blind, randomized, placebo-controlled study. Each subject > received either LDN or a placebo for 8 weeks, followed by one week without either, and > then a further 8 weeks on the alternate. The effects of LDN on quality of life was measured > using the multiple sclerosis quality of life inventory. During the study's time period, LDN > was able to show

significant benefit for mental health outcome measures but not for > physical outcomes. [Ed. Note: For details of the data we must await scheduled publication > in a medical journal.]> > Italian Researchers Present 6-Month Pilot Study of LDN for PPMS> > Dr. Maira Gironi and her colleagues of Milan, Italy presented a poster summary of their 6-> month study of LDN for Primary Progressive MS to the AAN conference in Chicago in April. > This open label study used a 4mg dosage of LDN in 40 patients. There were 5 dropouts, > most of which appeared unrelated to the drug. Endorphin levels were measured at > intervals and were seen to gradually increase throughout. This correlated with a general > trend of improvement in a number of efficacy measures. Significant improvements were > seen by the study's conclusion in both fatigue and depression. [Ed. Note: Detailed data > availability awaits

scheduled publication in a medical journal.]> > Crohn's Disease Trial at Penn State Seeks More Volunteers> > As of early May, Dr. Jill , Professor of Gastroenterology at Hershey Medical Center > (Pennsylvania State University), was still actively seeking more people with Crohn's disease > in order to complete her ongoing Phase II research study, which has received strong > funding from the National Institutes of Health. This effort may be aided by the recent > video produced by the local Philadelphia ABC TV news station, which highlighted the LDN > research work of both Dr. and Ian Zagon, PhD (see above). Patients interested in > volunteering for the research project should contact Bingaman, RN, at 717-531-> 8108.> > Book of Patients' Stories of LDN Use Planned> > Aletha Wittmann, whose husband experienced a dramatic reversal of his symptoms of MS

> with the use of LDN, is planning to collect and publish many detailed short stories from > LDN users, which will help others understand the actual experiences of those using the > drug. She explains that "The book will be non-profit, with any proceeds going towards > further LDN research or trials." For details on the book and how to contribute, see Aletha's > letter (http://www.low dose naltrexone.org/_mm/alethabook.pdf).> > Marked Increase in Television News Coverage of LDN> > Recent weeks have seen several reports produced by major broadcast networks concerning > low dose naltrexone use:> > CBS TV News Broadcast: Naltrexone "May Treat Other Diseases." Dr. Max Gomez, > award-winning medical journalist for CBS-TV New York, presented a report on LDN on > May 26. The video included an interview with Ronnie , who has had primary > progressive MS

for some 20 years and is now wheelchair bound. She feels that her use of > LDN for the past year has dispelled her fatigue and restored her mental acuity. Others > interviewed were Gluck, MD, editor of this website, and Victor Falah, RPh, the chief > pharmacist of Irmat compounding pharmacy. (See http://tinyurl.com/6x47zl.)> > ABC News Reports: LDN a "Wonder Drug?" On May 21, ABC Action News of > Philadelphia reported the story of Pam Sweigart of PA whose debilitating Crohn's disease > was interfering with her ability to care for her youngsters, until she obtained relief through > the use of low dose naltrexone. The report also features interviews with two Penn State > professors: Dr. Jill , author of the first published clinical trial of LDN in humans, as > well as Dr. Ian Zagon, who for over 20 years has pioneered animal research on endorphins > as well as on LDN. (See

http://tinyurl.com/5lv26n.)> > CBS News: "Wonder drug" LDN Could Help Treat Cancer, MS. This story, broadcast in > February, appeared on CBS 47 (WTEV-TV) of ville, Florida, and features an interview > with Lori Miles, an MS sufferer who can now walk again, thanks to LDN. Also quoted in the > piece is Dr. Kantor, neurologist and director of the Comprehensive Multiple > Sclerosis Program at the Shands ville Neuroscience Institute: "I would like all of us > to write to our congressmen, ask the FDA and NIH—National Institutes of Health—to fund > more research about LDN." (See http://www.youtube.com/watch?v=Kz52KK5IhOc.)> > (Additional changes/updates have been made to the LDN Homepage.)> > LDN Website Editors > email@...>

[Guest guest]

Ok, thanks. That is pretty disappointing. A lot of people on this list seem to see physical results rather quickly. So it is placebo effect? What type of MS patients were they using in the study? There are several levels, and one has to wonder if they were looking at specific types, like SPMS or RRMS etc. Or........did they follow the protocols seen most common here and tested previously. What dose, what time, etc. It will be interesting to find all this out. BCn T <callisto_11uk@...> wrote: Hi , Here's the original text from 's update: > > Outline of Double-Blind Trial of LDN in MS Presented at AAN> > Dr. Bruce Cree and colleagues of the University of California at San Francisco delivered a > poster presentation summary of their recently completed trial to the American Academy of > Neurology (AAN) conference in April 2008 in Chicago. Eighty patients with MS were > involved in this double-blind, randomized, placebo-controlled study. Each subject > received either LDN or a placebo for 8 weeks, followed by one week without either, and > then a further 8 weeks on the alternate. The effects of LDN on quality of life was measured > using the multiple sclerosis quality of life inventory. During the study's time period, LDN > was able to show significant benefit for

mental health outcome measures but not for > physical outcomes. [Ed. Note: For details of the data we must await scheduled publication > in a medical journal.] - n _______________________> Thanks for the updates ! > > - I have a comment/question regarding the trial conducted by Dr Bruce Cree (below):> > Are there any more details about the time of day LDN was administered/taken by the trial subjects? I seem to recall a previous

study (Italian? German?) showed similar results but it transpired that the subjects took LDN in the morning, not at night, ...which, it would seem, would affect the efficacy of the drug. I wondered if this was perhaps the reason why Dr Cree's trial showed such dissappointing results as far as physical improvements were concerned. It's a thought isnt it?> Or perhaps eight weeks was too short a time to show measureable physical improvements maybe?> Perhaps we'll just have to wait for the full details of the trial to be published to answer these questions though. > All the best to everyone on the board, > n xx> (UK)

[Guest guest]

My understanding is that they used what is essentially a depression chart. I don't think they were set up to demonstrate physical changes. There were no blood work ups, MRI's or on hands type of testing included as far as I know. Just filling out questionnaires. That is all they could afford for $50,000. At least they gave it a go.

All my best

Aletha

Re: [low dose naltrexone] Re: LDN Website Update - May 31, 2008

Ok, thanks. That is pretty disappointing. A lot of people on this list seem to see physical results rather quickly. So it is placebo effect? What type of MS patients were they using in the study? There are several levels, and one has to wonder if they were looking at specific types, like SPMS or RRMS etc. Or........did they follow the protocols seen most common here and tested previously. What dose, what time, etc.

It will be interesting to find all this out.

BCn T <callisto_11uk (DOT) co.uk> wrote:

Hi ,

Here's the original text from 's update:

> > Outline of Double-Blind Trial of LDN in MS Presented at AAN> > Dr. Bruce Cree and colleagues of the University of California at San Francisco delivered a > poster presentation summary of their recently completed trial to the American Academy of > Neurology (AAN) conference in April 2008 in Chicago. Eighty patients with MS were > involved in this double-blind, randomized, placebo-controlled study. Each subject > received either LDN or a placebo for 8 weeks, followed by one week without either, and > then a further 8 weeks on the alternate. The effects of LDN on quality of life was measured > using the multiple sclerosis quality of life inventory. During the study's time period, LDN > was able to show significant benefit for mental health outcome measures but not for > physical outcomes. [Ed. Note: For details of the data we must await scheduled publication > in a medical journal.]

- n _______________________> Thanks for the updates ! > > - I have a comment/question regarding the trial conducted by Dr Bruce Cree (below):> > Are there any more details about the time of day LDN was administered/taken by the trial subjects? I seem to recall a previous study (Italian? German?) showed similar results but it transpired that the subjects took LDN in the morning, not at night, ...which, it would seem, would affect the efficacy of the drug. I wondered if this was perhaps the reason why Dr Cree's trial showed such dissappointing results as far as physical improvements were concerned. It's a thought isnt it?> Or perhaps eight weeks was too short a time to show measureable physical improvements maybe?> Perhaps we'll just have to wait for the full details of the trial to be published to answer these questions though. > All the best to everyone on the board, > n xx> (UK)